MESO
Mesoblast Limited
There isn't enough reported data to score MESO yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MESO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MESO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MESO PE Valuation
MESO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MESO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect MESO's losses to grow, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MESO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.07 | +$0.02 |
| Q2 2025 | -$0.08 | +$0.05 |
| Q4 2024 | -$0.09 | +$0.09 |
| Q2 2024 | -$0.13 | +$0.08 |
| Q4 2023 | -$0.18 | +$0.05 |
| Q2 2020 | -$0.28 | +$0.06 |
| Q2 2019 | -$0.34 | -$0.20 |
MESO is still losing money, but far less than before: $0.07 per share over the past year, against $0.34 at its worst in mid-2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MESO in the latest year-over-year earnings comparison.
MESO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $51.3M | +1527% |
| Q2 2025 | $14M | +459% |
| Q4 2024 | $3.2M | -6.8% |
| Q2 2024 | $2.5M | +18% |
| Q4 2023 | $3.4M | +59% |
| Q2 2023 | $2.1M | -3.9% |
| Q1 2023 | $1.9M | -3.6% |
| Q4 2022 | $2.1M | -10% |
MESO has the stronger quarterly revenue trend. Revenue is up 1,415% for MESO versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -77% | +886 points |
| Q2 2025 | -385% | +641 points |
| Q4 2024 | -1512% | -551 points |
| Q2 2024 | -2208% | -1057 points |
| Q4 2023 | -963% | +164 points |
| Q2 2023 | -1027% | -60 points |
| Q1 2023 | -962% | +100 points |
| Q4 2022 | -1151% | -59 points |
MESO's operating margin was −77% last quarter, up 886 points from the same quarter a year ago, near the top of its range since 2018.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MESO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$30.8M | -$10M |
| Q4 2024 | -$20.8M | +$5.8M |
| Q1 2023 | -$16.3M | -$731K |
MESO and OSCR do not have enough comparable growth data to identify a winner.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
MESO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +84.3M shares |
| 1 year | +203% | +866M shares |
| 3 years | +277% | +949M shares |
| 5 years | +389% | +1B shares |
| Available history | +424% | +1B shares |
MESO has 1.3B diluted shares, up 203% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over MESO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MESO Net Leverage
MESO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MESO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 35.5 | Neutral |
MESO's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MESO PE vs Healthcare Sector
MESO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MESO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 6.1% below |
| 20 week MA | $15.1 | 13% below |
| 50 week MA | $15.7 | 17% below |
| 100 week MA | $15.2 | 14% below |
| 200 week MA | $10.5 | 25% above |
MESO has fallen below most of its moving averages, though it's still 25% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MESO on trend strength, trading above more of its moving averages.
MESO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $17.5 | +18% |
| 2021 | $17.5 | $9.64 | -45% |
| 2022 | $9.64 | $5.95 | -38% |
| 2023 | $5.95 | $2.20 | -63% |
| 2024 | $2.20 | $17.5 | +697% |
| 2025 | $17.5 | $19.5 | +11% |
| 2026 YTD | $19.5 | $13.1 | -33% |
MESO's yearly returns have swung widely, from +697% in 2024 to −63% in 2023. It's down 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MESO on returns for 2026, with the stronger performance.